The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

T-DXd regimens improved pathologic complete response and safety profiles compared to ddAC-THP in high-risk, HER2-positive early breast cancer. Patient-reported outcomes showed better physical ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. | Pfizer has rolled out detailed trial ...

Nearly 580 participants will be enrolled at sites across Europe, Asia, South America, and North America.

In the January 2025 presentation, Jazz Pharmaceuticals expects zanidatamab to potentially receive approval and be launched as ...

Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.

AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...

Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...

The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with ...